



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Managing central venous access during a health care crisis



Tristen T. Chun, MD, MS,^a Dejah R. Judelson, MD,^b David Rigberg, MD,^a Peter F. Lawrence, MD,^a Robert Cuff, MD,^c Sherene Shalhub, MD, MPH,^d Max Wohlaer, MD,^e Christopher J. Abularrage, MD,^f Papapetrou Anastasios, MD, PhD, MSc,^g Shipra Arya, MD, SM,^h Bernadette Aulivola, MD, MS,ⁱ Melissa Baldwin, MD,^j Donald Baril, MD,^a Carlos F. Bechara, MD,^j William E. Beckerman, MD,^k Christian-Alexander Behrendt, MD,^l Filippo Benedetto, MD,^m Lisa F. Bennett, MD, MS,ⁿ Kristofer M. Charlton-Ouw, MD,^o Amit Chawla, MD,^p Matthew C. Chia, MD,^q Sungsin Cho, MD, PhD,^r Andrew M. T. L. Choong, MBBS, PhD,^s Elizabeth L. Chou, MD,^t Anastasiadou Christiana, MD,^g Raphael Coscas, MD, PhD,^u Giovanni De Caridi, MD, PhD,^m Sharif Ellozy, MD,^v Yana Etkin, MD,^w Peter Faries, MD,^j Adrian T. Fung, MD,^x Andrew Gonzalez, MD, JD, MPH,^y Claire L. Griffin, MD,^z London Guidry, MD,^p Nalaka Gunawansa, MBBS, MS, MCh,^{aa} Gary Gwertzman, MD,^j Daniel K. Han, MD,^j Caitlin W. Hicks, MD, MS,^f Carlos A. Hinojosa, MD, MSc,^{bb} York Hsiang, MB, ChB, MHSc,^x Nicole Ilonzo, MD,^j Lalithapriya Jayakumar, MD,^{cc} Jin Hyun Joh, MD, PhD,^f Adam P. Johnson, MD, MPH,^{dd} Loay S. Kabbani, MD, MHSA,^{ee} Melissa R. Keller, MD, PhD,^{ff} Manar Khashram, MBChB, PhD,^{gg} Issam Koleilat, MD,^{hh} Bernard Krueger, MD,ⁱⁱ Akshay Kumar, MD,^{jj} Cheong Jun Lee, MD,^{kk} Alice Lee, DO,^{ee} Mark M. Levy, MD,^{ll} C. Taylor Lewis, MD,^v Benjamin Lind, MD,^{kk} Gabriel Lopez-Pena, MD,^{bb} Jahan Mohebbali, MD, MPH,^t Robert C. Molnar, MD, MS,^{ff} Nicholas J. Morrissey, MD,^{dd} Raghu L. Motaganahalli, MD,^y Nicolas J. Mouawad, MD, MPH, MBA,^{ff,mm} Daniel H. Newton, MD,^{ll} Jun Jie Ng, MD,^s Leigh Ann O'Banion, MD,ⁿⁿ John Phair, MD,^j Zoran Rancic, MD, MSc, PhD,ⁱⁱ Ajit Rao, MD,^j Hunter M. Ray, MD,^o Aksim G. Rivera, MD,^{hh} Limael Rodriguez, MD,^e Clifford M. Sales, MD, MBA,^{oo} Garrett Salzman, MD,^a Mark Sarfati, MD,^z Ajay Savlania, MCh,^{pp} Andres Schanzer, MD,^b Mel J. Sharafuddin, MD, MS,^{qq} Malachi Sheahan, MD,^p Sammy Siada, DO,^e Jeffrey J. Siracuse, MD, MBA,^{rr} Brigitte K. Smith, MD,^z Matthew Smith, MD, PhD,^v Ina Soh, MD, MS,^{ss} Rebecca Sorber, MD,^f Varuna Sundaram, MD,^v Scott Sundick, MD, MS,^{oo} Tadaki M. Tomita, MD,^q Bradley Trinidad, MD,^{tt} Shirling Tsai, MD,^{uu} Ageliki G. Vouyouka, MD,^j Gregory G. Westin, MD, MAS,^y Michael S. Williams Jr, MD,^{vv} Sherry M. Wren, MD,^h Jane K. Yang, MD,^a Jeniann Yi, MD, MS,^e Wei Zhou, MD,^{tt} Saqib Zia, MD,^{www} and Karen Woo, MD, MS,^a *Los Angeles, Palo Alto, and Fresno, Calif; Worcester and Boston, Mass; Grand Rapids, Detroit, East Lansing, and Bay City, Mich; Seattle, Wash; Aurora and Denver, Colo; Baltimore, Md; Athens, Greece; Maywood, Chicago, and Evanston, Ill; New York, Hempstead, and Bronx, NY; New Brunswick, Westfield, and Newark, NJ; Hamburg, Germany; Messina, Italy; Houston, San Antonio, and Dallas, Tex; New Orleans, La; Seoul, South Korea; Singapore; Paris, France; Vancouver, British Columbia, Canada; Indianapolis, Ind; Salt Lake City, Utah; Colombo, Sri Lanka; Mexico City, Mexico; Auckland, New Zealand; Zurich, Switzerland; Gurgaon and Chandigarh, India; Richmond, Va; Iowa City, Iowa; Phoenix and Tucson, Ariz; and St. Louis, Mo*

From the Division of Vascular Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles^a; the Division of Vascular and Endovascular Surgery, Department of Surgery, University of Massachusetts Medical School, Worcester^b; the Division of Vascular Surgery, Department of Surgery, Spectrum Health/Michigan State University, Grand Rapids^c; the Division of Vascular Surgery, Department of Surgery, University of Washington, Seattle^d; the Division of Vascular Surgery, Department of Surgery, University of Colorado School of Medicine, Aurora^e; the Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Johns Hopkins Medical Institutions, Baltimore^f; the Department of Vascular Surgery, General Hospital of Athens KAT, Athens^g; the Department of Surgery Stanford University School of Medicine, Palo Alto^h; the Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Loyola University Medical Center, Maywoodⁱ; the Division of Vascular Surgery, Department of Surgery, Icahn School of Medicine at Mount Sinai, New York^j; the Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Rutgers Robert Wood Johnson, New Brunswick^k; the Department of Vascular Medicine, Research Group GermanVasc, University Medical Center Hamburg-Eppendorf, Hamburg^l; the Division of Vascular Surgery, University of Messina, Messina^m; the Rose Medical Center, HealthOne, Denverⁿ; the Department of Cardiothoracic and Vascular Surgery,

McGovern Medical School at University of Texas Health Science Center at Houston, Houston^o; the Division of Vascular Surgery, Department of Surgery, Louisiana State University Health Sciences Center, New Orleans^p; the Division of Vascular Surgery, Department of Surgery, Northwestern University, Chicago^q; the Division of Vascular Surgery, Department of Surgery, Kyung Hee University School of Medicine, Seoul^r; the Division of Vascular and Endovascular Surgery, National University Heart Centre, Singapore^s; the Division of Vascular Surgery, Department of Surgery, Massachusetts General Hospital, Boston^t; the Vascular Surgery Department, Ambroise Paré University Hospital, AP-HP, Boulogne-Billancourt, Paris^u; the Division of Vascular and Endovascular Surgery, Department of Surgery, Weill Cornell Medicine, New York^v; the Division of Vascular and Endovascular Surgery, Department of Surgery, Zucker School of Medicine at Hofstra/Northwell, Hempstead^w; the Division of Vascular Surgery, Department of Surgery, University of British Columbia, Vancouver^x; the Division of Vascular Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis^y; the Vascular Division, Department of Surgery, University of Utah, Salt Lake City^z; the Department of Vascular and Transplant Surgery, National Institute of Nephrology Dialysis and Transplantation, Colombo^{aa}; the Division of Vascular and Endovascular Surgery, Department of Surgery, Universidad Nacional Autónoma de México, Instituto

ABSTRACT

Objective: During the COVID-19 pandemic, central venous access line teams were implemented at many hospitals throughout the world to provide access for critically ill patients. The objective of this study was to describe the structure, practice patterns, and outcomes of these vascular access teams during the COVID-19 pandemic.

Methods: We conducted a cross-sectional, self-reported study of central venous access line teams in hospitals afflicted with the COVID-19 pandemic. To participate in the study, hospitals were required to meet one of the following criteria: development of a formal plan for a central venous access line team during the pandemic; implementation of a central venous access line team during the pandemic; placement of central venous access by a designated practice group during the pandemic as part of routine clinical practice; or management of an iatrogenic complication related to central venous access in a patient with COVID-19.

Results: Participants from 60 hospitals in 13 countries contributed data to the study. Central venous line teams were most commonly composed of vascular surgery and general surgery attending physicians and trainees. Twenty sites had 2657 lines placed by their central venous access line team or designated practice group. During that time, there were 11 (0.4%) iatrogenic complications associated with central venous access procedures performed by the line team or group at those 20 sites. Triple lumen catheters, Cordis (Santa Clara, Calif) catheters, and nontunneled hemodialysis catheters were the most common types of central venous lines placed by the teams. Eight (14%) sites reported experience in placing central venous lines in prone, ventilated patients with COVID-19. A dedicated line cart was used by 35 (59%) of the hospitals. Less than 50% (24 [41%]) of the participating sites reported managing thrombosed central lines in COVID-19 patients. Twenty-three of the sites managed 48 iatrogenic complications in patients with COVID-19 (including complications caused by providers outside of the line team or designated practice group).

Conclusions: Implementation of a dedicated central venous access line team during a pandemic or other health care crisis is a way by which physicians trained in central venous access can contribute their expertise to a stressed health care system. A line team composed of physicians with vascular skill sets provides relief to resource-constrained intensive care unit, ward, and emergency medicine teams with a low rate of iatrogenic complications relative to historical reports. We recommend that a plan for central venous access line team implementation be in place for future health care crises. (J Vasc Surg 2020;72:1184-95.)

Keywords: Central venous access; Central line teams; Iatrogenic injuries

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused 7,293,307 cases of coronavirus disease 2019 (COVID-19) worldwide (as of June 10, 2020) and 413,126 deaths. Of those cases, 1,990,112 have been in the United States, with 112,441 associated deaths between February 6, 2020, and June 10, 2020.¹ Approximately 5% to 10% of patients with COVID-19 require admission to the intensive care unit (ICU) and

mechanical ventilation.^{2,3} In these critically ill patients, the rates of septic shock and acute kidney injury are 20% and 15%, respectively.^{4,5} As a result, these patients often require central venous access for the infusion of vasoactive agents or hemodialysis.

In the COVID-19 crisis, overburdened health care systems throughout the world have had to address the need to provide central venous access for the

Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City^{bb}; the Vascular and Endovascular Division, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio^{cc}; the Department of Vascular Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York^{dd}; the Vascular Division, Department of Surgery, Wayne State University, Detroit^{ee}; the Department of Surgery, Michigan State University, East Lansing^{ff}; the Department of Surgery, University of Auckland, Auckland^{gg}; the Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx^{hh}; the Institute of Anesthesiology, Intensive Care Unit for Cardiovascular Surgery and Department of Vascular Surgery, University Hospital Zurich, Faculty of Medicine, University of Zurich, Zurichⁱⁱ; the Department of Cardiovascular and Thoracic Surgery, Medanta Hospital, Gurgaon^{jj}; the Division of Vascular Surgery, Department of Surgery, NorthShore University Health System, Evanston^{kk}; the Vascular Division, Department of Surgery, Virginia Commonwealth University, Richmond^{ll}; the Vascular and Endovascular Surgery, McLaren Health System, Bay City^{mm}; the Department of Surgery, Vascular Division, University of California San Francisco at Fresno, Fresnoⁿⁿ; The Cardiovascular Care Group, Westfield^{oo}; the Postgraduate Institute of Medical Education and Research, Chandigarh^{pp}; the Department of Vascular Surgery, University of Iowa Healthcare, Iowa City^{qq}; the Department of Surgery, Boston University School of Medicine, Boston^{rr}; the Division of Vascular

and Endovascular Surgery, Mayo Clinic, Phoenix^{ss}; the Vascular Division, Department of Surgery, University of Arizona, Tucson^{tt}; the Vascular Division, Department of Surgery, VA North Texas Health Care Systems, Dallas^{uu}; the Vascular and Endovascular Division, Department of Surgery, St. Louis University School of Medicine, St. Louis^{vv}; and the Vascular Division, Department of Surgery, Rutgers New Jersey Medical School, Newark^{www}

This project was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant UL1TR001881 and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIDDK1K08DK107934).

Author conflict of interest: none.

Additional material for this article may be found online at www.jvascsurg.org.

Correspondence: Karen Woo, MD, Division of Vascular Surgery, Department of Surgery, University of California, Los Angeles, 200 UCLA Medical Plaza, Ste 526, Los Angeles, CA 90095 (e-mail: kwoo@mednet.ucla.edu).

The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.

0741-5214

Copyright © 2020 by the Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.jvs.2020.06.112>

unprecedented dramatic influx of critically ill patients, particularly during the surge period of the pandemic. As a result, the procedure of placing central venous access, which is normally a routine occurrence in critical care units, has created unique challenges during the COVID-19 pandemic, given the limited providers available to manage the extraordinary increase in critically ill patients. The limited resources may lead to central venous access procedures being performed by less experienced or overworked physicians, which results in an increased rate of serious complications.⁶ Furthermore, central venous access procedures can result in physicians' prolonged occupation by a single patient while the issues of other acutely ill patients are not being addressed. In the case of a COVID-19-positive patient, the central venous access procedure includes not only the time required to perform the procedure but also the additional time required to don and doff the added personal protective equipment (PPE) required.

During the COVID-19 pandemic, central venous access line teams have been developed at many hospitals throughout the world to handle the access needs of all patients in the hospital, freeing physicians with less experience in central venous access and those who are overburdened by acute and critical demands to focus on management of other patients requiring their attention.^{7,8} The teams often consist of vascular surgeons, general surgeons, interventional radiologists, anesthesiologists, intensivists, and interventional cardiologists who have been trained and have extensive experience in central venous access as well as experience in identifying and managing the complications associated with central venous access procedures.^{9,10} For example, to meet the increased demand for critical care providers at the University of Massachusetts, vascular surgeons formed a Surgical Workforce Access Team (SWAT) to best leverage the skill sets of vascular surgery division members and to provide the best service to the hospital and to their colleagues.⁷ At Mount Sinai Hospital in New York, physicians recognized a dramatic increase in the rate of central line complications and the resulting urgent vascular interventions. In response, the vascular surgeons created a line team.⁸

Whereas central line teams and protocols for line placement and management have been described in the past, those efforts have been focused on reducing central line-associated bloodstream infections rather than on addressing a pressing need during a health care disaster.¹¹⁻¹³ Within the context of early isolated single-institution reports, we sought to provide a multi-institutional experience of line teams during the pandemic. The objective of this study was to describe the structure, practice patterns, and outcomes of these line teams on central venous access procedures and their related complications.

ARTICLE HIGHLIGHTS

- **Type of Research:** Multicenter, cross-sectional cohort study of experiences with central venous access line teams during the COVID-19 pandemic
- **Key Findings:** Participants from 60 hospitals in 13 countries contributed data; 75% of line teams included a vascular surgery attending physician; 2657 central venous lines were placed at 20 of the participating sites, with 11 (0.41%) iatrogenic access complications associated with procedures performed by the line team.
- **Take Home Message:** Implementation of a dedicated central venous access line team during health care emergencies, with staffing by physicians with central venous access expertise, a dedicated line cart, specific anatomic sites for different venous access needs, and a method to track complications, can improve outcomes and reduce iatrogenic complications.

METHODS

We conducted a cross-sectional, self-reported study of structured central venous access line teams and the physician groups providing central venous access in hospitals afflicted by the COVID-19 pandemic. To participate in the study, hospitals were required to meet one of the following criteria: development of a formal plan for a central venous access line team during the pandemic; implementation of a central venous access line team during the pandemic; placement of central venous access by a designated practice group during the pandemic as part of routine clinical practice; or management of an iatrogenic complication related to central venous access in a patient with COVID-19.

This study was a collaborative effort between the Vascular Low Frequency Disease Consortium (VLFDC) and the Vascular Surgery COVID-19 Collaborative (VASCC). The VLFDC is a multi-institutional collaboration, initiated 20 years ago, designed to investigate uncommon vascular diseases.¹⁴ The VASCC was established on March 2, 2020, to study the impact of the ongoing COVID-19 pandemic on vascular surgical care,¹⁵ using an international registry.

The Institutional Review Board of the University of California Los Angeles (UCLA) deemed this study protocol exempt as a quality improvement project.

Database development. The primary investigators (K.W., T.C., D.J., D.R.) initially developed the registry data elements by determining factors important to the structure and function of central venous access line teams' experience of line placement during the pandemic as well as iatrogenic complications associated with line placement. The draft registry was reviewed by a group

Table I. Hospital characteristics and central venous line placement volume

	Hospitals with line team in place or planned (n = 44)	Groups placing lines at their hospital outside of line team (n = 14)
Hospital characteristics		
Urban	44 (100)	14 (100)
Academic university affiliated	34 (77)	11 (79)
Non-university-affiliated teaching	4 (9)	2 (14)
Community/private	3 (7)	1 (7)
Public	4 (9)	2 (14)
Veterans Affairs	1 (7)	5 (11)
Hospital size by baseline beds		
100-199	5 (11)	1 (7)
200-299	3 (7)	1 (7)
300-399	6 (14)	1 (7)
>400	30 (68)	11 (79)
Hospitals with line teams in place (n = 31)		
Line placements in previous 7 days ^a		NA
0-10	7 (23)	
10-20	9 (29)	
20-30	2 (7)	
30-40	2 (7)	
>40	11 (36)	

NA, Not applicable.
Values are reported as number (%).
^aLine placements in the 7 days preceding data entry into the study.

of physician investigators with central venous line placement expertise and revised in an iterative fashion until no further modifications were recommended by the group. This established the final standardized data set for collection that constitutes the basis of this study.

Data collection. The study was disseminated through the VLFDC and VASCC electronic mailing lists and social media. Study data were collected and managed using REDCap (Research Electronic Data Capture), a web-based data collection mechanism designed for research.¹⁶ Data entry into the registry opened on April 22, 2020, and closed on May 4, 2020. Study participants were required to record responses to all items in the database. Participants were contacted through electronic mail by the UCLA vascular research center for clarification of any discrepancies in the submitted data and missing data.

Participants were required to enter their hospital characteristics, use of central venous access line teams during the pandemic, types of patients and locations in which the line team services were offered, team composition, team availability, criteria for activation and termination of their services, and anatomic sites used for access. Each institution was asked to provide details about any iatrogenic complications associated with central venous

line placement and, if available, the total number of central venous access procedures performed during the time that the line team or designated practice group placing central lines was in place. Each institution was also given the opportunity to provide insight into successful management of central venous access during the pandemic.

RESULTS

Demographics. Participants from 60 hospitals in 13 countries contributed data to the study (Appendix A, online only). Fifty-eight of the hospitals had plans in place for a central venous access line team, had implemented the line team, or had a designated practice group placing central venous lines for the hospital outside of a formal line team structure. Two of the participating hospitals had not developed or implemented a line team or designated a group to place lines but had managed an iatrogenic complication related to central venous access in a patient with COVID-19. Most of the hospitals that participated were urban, academic, university-affiliated hospitals with >400 beds (Table I). Thirty-one of the hospitals had developed and implemented a central venous access line team specifically for the pandemic, whereas five hospitals had a plan for a line team but had not yet implemented it. Twenty-five of the




Fig 1. Central venous access line team composition. *Anes*, Anesthesia; *Card*, cardiology; *CTS*, cardiothoracic surgery; *GS*, general surgery; *IR*, interventional radiology; *Med*, medicine; *VS*, vascular surgery. *Percentage of line teams that include attending physicians and trainees of each specialty.

participating hospitals had a physician group placing central venous lines as part of their routine clinical practice, without being designated a line team. Eight of the hospitals that implemented a line team had a central venous access line team in existence before the pandemic, with four making no changes once the pandemic started. Two changed the PPE protocols for their line teams with the onset of the pandemic. One made services available on the weekends and ensured that attending physicians were physically present in the hospital at all times. One had a pre-existing medical proceduralist team that remained in place with the addition of a surgical team to supplement or to take over their responsibilities when the medical specialists were called to take care of patients.

Central venous access line teams were most commonly composed of vascular and general surgery attending physicians and trainees, with some hospitals including attending physicians and trainees of other specialties, such as interventional radiology and anesthesiology (Fig 1). Nearly all of the line teams served or intended to serve patients who had tested positive for the SARS-CoV-2 virus (COVID-19+) in the ICU setting (42 [96%]) as well as patients under investigation for SARS-CoV-2 infection (COVID-19PUI) in the ICU (40 [90%]). Fewer line teams included patients who had tested negative for the SARS-CoV-2 virus (COVID-19-) in the ICU (28 [66%]). Most line teams also provided service for COVID-19+ and COVID-19PUI patients on the floor setting (28 [64%]). Some line teams provided services for COVID-19+ (25 [57%]) and COVID-19PUI (22 [50%]) patients in the emergency department.

The plan to use the services of a central venous access line team during the pandemic was most commonly initiated by the vascular surgery division or department

(15 [34%]) or critical care team (11 [25%]). The burden of COVID-19+ patients exceeding a critical threshold at the institution, where providers with training were present but overwhelmed, was cited as one of the reasons for implementing the line team by 22 (50%) of the hospitals. The importance of minimizing line placement complications was cited as one of the reasons for implementation by 23 (52%) of the hospitals. The majority of line teams made their services available daily at all hours (28 [64%]), whereas at some hospitals (5 [12%]), the timing of line team service availability varied by the phase of the pandemic and the stress on the resources in their hospital. These hospitals required exceeding a critical volume threshold for the central venous access line team to become activated. The criteria for terminating the line team services included a combination of reduction of hospitalized COVID-19 patients to below a critical threshold (64%), increased availability of other providers with line placement skills (25%), and line team members returning to regular duties (41%).

Central venous access line team characteristics. In the 58 hospitals placing lines, 6 sites (10%) had no trainees involved in central venous line placement procedures. At 11 hospitals (19%), the attending physician was in the room during every line placement procedure. Of the 41 remaining hospitals, 30 had trainees that were at least at postgraduate year 3 level performing the central venous access procedures, with attending physicians immediately available.

Triple lumen catheters (TLCs), Cordis (Santa Clara, Calif) catheters, nontunneled hemodialysis catheters (HDCs), and tunneled HDCs were the most common types of central venous lines placed (Fig 2). Six of the hospitals also performed peripherally inserted central catheters; however, they reported that this practice was in place before the pandemic and remained unchanged.

Among the 44 hospitals with line teams in place or planned, additional line team services provided, beyond central venous line placement during the COVID-19 pandemic, included arterial line placement (82.8%), orogastric and nasogastric tube placement (18%), tube thoracostomy (16%), Foley catheter placement (10%), intubation (7%), tracheostomy (5%), gastric tube placement (2%), and rectal tube placement (2%). For the 31 hospitals with line teams in place, the reported numbers of central venous line placements performed during the 7 days preceding participation in this study varied from <10 to >40, with the most common category being >40 (Table I).

Anatomic considerations. The internal jugular veins were the preferred sites for TLC and HDC placement before the COVID-19 pandemic (Table II); these continued to be the preferred sites during the pandemic for COVID-19+, COVID-19PUI, and COVID-19- patients. However, during the pandemic, the participating sites




Fig 2. Types of central venous lines placed by line teams (n = 44). AV ECMO, Arteriovenous extracorporeal membrane oxygenation; NTHDC, nontunneled hemodialysis catheter; PD, peritoneal dialysis; PICC, peripherally inserted central catheter; THDC, tunneled hemodialysis catheter; TLC, triple lumen catheter; VV ECMO, venovenous extracorporeal membrane oxygenation. Others include Infusa-ports, Hickman catheters, and small-bore sheaths for potential ECMO candidates.

used the internal jugular and subclavian veins less frequently than before the pandemic, whereas the great saphenous and popliteal veins were used more frequently. For supine COVID-19+ patients, the first choice for TLC placement was the right internal jugular vein in 31 (52.5%) hospitals and the left internal jugular vein in 22 (37.3%). The first-choice location for HDC placement was the right internal jugular vein in 46 (82.1%) of the hospitals. Similar patterns were found for COVID-19PUI patients (Table II).

Most participating sites considered similar anatomic locations for COVID-19+ and COVID-19- patients; however, 18 (30.5%) sites reported that their preferences for venous access in COVID-19+ patients were different from those in COVID-19- patients, with the most common reason being the ease of accessibility and the likelihood of kinking the catheters if the patient required prone positioning. Other considerations included the risk of pneumothorax and the proximity to the patient's airway, potentially increasing the risk of infection to the providers performing the procedure. In addition, 16 (27%) sites considered renal failure or impending renal failure requiring dialysis a factor in choosing anatomic location for TLCs or HDCs. Most reported preserving the right internal jugular vein for HDCs and avoiding the femoral veins for HDCs for potential prone positioning required for COVID-19 treatment.

Eight (14%) sites reported experience with placing central venous lines in prone, ventilated COVID-19+ patients, with no associated complications. Six of the sites always delayed line placement until the patient returned to the supine position, or they requested that the patient be returned to the supine position for the procedure. One

site placed the lines with the patient remaining in the prone position. Two sites placed the line with the patient remaining in the prone position if they could safely access the vein laterally. In this population of patients who required prone positioning, TLCs continued to be placed in either the right or the left internal jugular vein, the femoral vein, or the great saphenous vein. HDCs were placed exclusively in the right internal jugular vein. Three lines were placed while the patient remained in the prone position: a TLC placed in the popliteal vein; a nontunneled HDC placed in the right internal jugular vein; and a TLC placed in the right internal jugular vein. Standard line placement techniques were used with ultrasound guidance and percutaneous Seldinger technique.

All 58 sites placing central venous lines during the COVID-19 pandemic used ultrasound guidance during line placement, and nearly all participants (52 [90%]) reported obtaining a chest radiograph to confirm line placement for internal jugular or subclavian lines in COVID-19+ patients. Those who did not obtain a radiograph acknowledged that this deviated from their normal practice. Their rationale for not using radiography was to limit exposure of hospital staff and radiology technologists while conserving PPE.

Supplies and PPE utilization. A dedicated line cart was used at 35 (59%) hospitals. The most common items stored in these line carts were kits for TLCs, HDCs, Cordis catheters (100%), sterile gloves (97%), sterile gowns (97%), sterile preparation sticks (94%), sterile gauze (94%), ultrasound probe covers (94%), selection of syringes (91%), sterile saline flushes (91%), sutures (91%), masks (91%), and bouffant hats (85%; Appendix B, online only).

PPE utilization patterns by line teams in COVID-19+ patients and COVID-19PUI patients were similar (Table III). A small but significant number of line teams continued to use N95 masks with or without surgical masks, even in COVID-19- patients (Table III). When asked if hospitals experienced an increased incidence of needle sticks to providers associated with central line placement during the COVID-19 pandemic, 28 (47%) responded no and 31 (52%) did not know.

Prevention and management of thrombosed central lines. Less than 50% (24 [41%]) of the participating sites in this study reported managing thrombosed central lines in COVID-19+ patients: 19 (33%) sites reported managing at least one thrombosed TLC, 21 (36%) HDC, and 2 (3%) Cordis catheters. More than half of the sites (32 [54%]) believed that central lines were more likely to thrombose in COVID-19+ patients compared with COVID-19- patients because of hypercoagulability. Most also believed that HDCs were more likely than any other type of central venous lines to thrombose in COVID-19+ patients.

Table II. Anatomic preferences for central venous catheter placements by COVID-19 status

	R IJ	L IJ	R SC	L SC	Fem	GSV	Pop
All anatomic locations considered viable							
Before pandemic	59 (97)	58 (95)	41 (67)	39 (64)	52 (85)	2 (3)	0 (0)
COVID-19+	52 (85)	50 (82)	27 (44)	26 (43)	48 (79)	4 (7)	2 (3)
COVID-19PUI	55 (90)	51 (84)	27 (44)	27 (44)	49 (80)	4 (7)	1 (2)
COVID-19–	59 (97)	58 (95)	34 (56)	32 (53)	49 (80)	2 (3)	0 (0)
First choice for supine patient							
COVID-19+							
TLC	31 (53)	22 (37)	2 (3)	0 (0)	4 (7)	0 (0)	0 (0)
HDC	46 (82)	0 (0)	2 (3)	0 (0)	8 (14)	0 (0)	0 (0)
COVID-19PUI							
TLC	30 (51)	23 (39)	2 (3)	0 (0)	4 (7)	0 (0)	0 (0)
HDC	45 (80)	0 (0)	2 (3)	0 (0)	9 (16)	0 (0)	0 (0)
COVID-19–, Patient who has not tested positive for SARS-CoV-2 virus; COVID-19+, patient who has tested positive for SARS-CoV-2 virus; COVID-19PUI, patient under investigation for SARS-CoV-2 infection; Fem, femoral vein; GSV, great saphenous vein; HDC, hemodialysis catheter; L IJ, left internal jugular vein; L SC, left subclavian vein; Pop, popliteal vein; R IJ, right internal jugular vein; R SC, right subclavian vein; TLC, triple lumen catheter. Values are reported as number (%).							

Table III. Personal protective equipment (PPE) used during placement of central venous lines in populations by COVID-19 status

	COVID-19+	COVID-19PUI	COVID-19–
Surgical mask without N95	1 (2)	2 (3)	41 (67)
N95 without surgical mask	15 (25)	13 (21)	6 (10)
N95 with surgical mask over	45 (74)	46 (75)	12 (20)
Powered air-purifying respirator	10 (16)	8 (13)	2 (3)
Face shield	54 (89)	55 (90)	36 (59)
Gown	55 (90)	54 (89)	55 (90)
Bunny suit with hood	5 (8)	4 (7)	0 (0)
Bunny suit without hood	3 (5)	3 (5)	0 (0)
Bouffant/surgical cap	52 (85)	52 (85)	48 (79)
Goggles	2 (3)	1 (2)	0 (0)
COVID-19+, Patient who has tested positive for SARS-CoV-2 virus; COVID-19PUI, patient under investigation for SARS-CoV-2 infection; COVID-19–, patient who has not tested positive for SARS-CoV-2 virus. Values are reported as number (%).			

Only 13 (22%) participating sites recommended varying types of routine anticoagulation in COVID-19+ patients to maintain central line patency, including prophylactic dosing of unfractionated heparin (four sites), therapeutic dosing of unfractionated heparin (one site), prophylactic dosing of low-molecular-weight heparin (five sites), and therapeutic dosing of low-molecular-weight heparin (two sites). The two remaining hospitals anticoagulated all COVID-19+ patients, regardless of whether the patient had a central venous access line in place. The majority of the participants who recommended anticoagulation were concerned about a high rate of thrombosis in COVID-19+ patients and recommended anticoagulation to minimize resource utilization.

Only seven (12%) participating sites were routinely changing central lines. Of those seven sites, five reported that routine changing of lines was part of their regular practice, regardless of the pandemic. One site changed the line every 3 days, one every 4 days, four every 7 days, and one every 8 days.

Complications and deaths. Twenty participating sites reported 2657 lines placed by their designated group or line team in COVID-19+, COVID-19PUI, and COVID-19– patients; there were 11 (0.4%) iatrogenic complications associated with central venous access line placement procedures performed by the designated group or line team at those sites. These consisted of two inadvertent placements of a catheter into an artery, seven instances of

Table IV. Iatrogenic complications of central venous line placement in COVID-19+ patients managed by participating sites

Complication	Total No. of cases	Cases related to line team procedure	Anatomic location				Initial management strategy	Initial management success		
			IJ/ carotid	SC	Femoral	Other				
Inadvertent arterial puncture with wire in place before catheter placement	3	0	2	0	1		Pull line and hold pressure (1)	Yes		
									Open surgical repair (1)	Yes
									Other (1)	^a
Inadvertent arterial puncture with dilator in place before catheter placement	2	0	1	0	0	Descending aorta	Pull line and hold pressure (1)	Yes		
									Endovascular management with stent (1)	Yes
Inadvertent arterial placement with catheter still remaining in artery	16	1	5	6	4	Brachiocephalic artery	Pull line and hold pressure (5)	Yes		
									Endovascular management with balloon (2)	Yes
									Closure device (1)	Yes
									Endovascular management with stent graft (1)	Yes
									Open surgical repair (3)	Yes
									Used as arterial line, then pulled (1)	Yes
									Other (3)	^a
Inadvertent arterial puncture with no catheter remaining in artery but active extravasation present	2	0	0	1	1		Pull line and hold pressure (2)	Yes		
Catheter or wire fracture/ embolization	3	0	0	0	1	Aorta Right atrium	Open surgical retrieval (1) Anticoagulation (2)	Yes		
Hematoma or active bleeding at catheter site with catheter in place and catheter in correct position	10	6	8	1	1		Pull line and hold pressure (10)	Yes		
Pneumothorax	11	1	4	5	0	2 unknown	Tube thoracostomy (11)	Yes		
Air embolism	1	1	1	0	0		None attempted	No		

IJ, Internal jugular; *SC*, subclavian.
^aSee text.

hematoma or active bleeding at catheter sites, one instance of pneumothorax, and one air embolism. The air embolism was in a COVID-19+ patient who was not intubated, and the patient died shortly thereafter. This

was the only death directly related to an iatrogenic venous access complication.

A total of 48 iatrogenic complications of central venous line placement in the COVID-19+ population were

managed by 23 (38%) participating sites, including complications associated with procedures performed by providers outside of their line team or designated group (Table IV). The most common type of complication was inadvertent placement of a catheter into an artery. In 20 of the complications, the participating site believed that something could have been done differently during the initial access attempt to prevent the complication. In almost all of these cases, the participating site believed that a combination of a more experienced operator, meticulous use of ultrasound, and maintaining wire control at all times could have prevented the complication.

With respect to the COVID-19+ population, in one case of inadvertent puncture of the artery, the wire was left in the femoral artery and the patient was anticoagulated because the patient was deemed too unstable for intervention. In three of the cases of inadvertent placement of a catheter into an artery, the patient was deemed too unstable from COVID-19 to undergo an intervention. In all but three of the complications in the COVID-19+ population, the participating sites indicated that they would have managed the iatrogenic complication in a COVID-19- patient in a manner similar to what was done in the COVID-19+ patient. For three complications, the sites stated they may have considered more aggressive surgical or interventional management if the patient had not been COVID-19+.

DISCUSSION

We describe the formation, implementation, and results of dedicated central venous access line teams led by physicians with central venous access expertise during the COVID-19 pandemic. These dedicated line teams served as an invaluable resource in stressed health care systems. This is aptly demonstrated by the 2657 lines placed by 20 of the line teams. Each of these lines represents an instance in which the line team enabled the ICU team to focus on the care of an unprecedented high volume of critically ill patients, rather than spend time preparing for the procedure, donning and doffing PPE, and performing the procedure. These line teams represent “bringing together elements to ensure an effective response,” which is a key point that is repeatedly emphasized in disaster management.¹⁷

The rapid spread of the pandemic exposed a lack of disaster preparedness in hospitals worldwide.¹⁸ Most health care disasters occur without notice.¹⁹ To optimize outcomes during a disaster, plans for managing a disaster need to be in place.^{17,19} The lessons learned from this initial line service experience can be readily applied to future health care crises and future surges of the COVID-19 pandemic. In fact, at the time of this writing (June 10, 2020), stay-at-home orders are being lifted across the United States. Since the stay-at-home order was lifted in Arizona on May 16, cases have increased by 108% in that state, with an associated

increase in hospitalizations and strain on the health care system.²⁰

Vascular surgeons are uniquely trained to lead dedicated central venous access line teams because a vascular practice usually encompasses routine percutaneous arterial and venous access, invariably using ultrasound guidance. The technical skills necessary to perform a high volume of these procedures, with a low complication rate, are critical for these teams to be of value. Based on the experiences of the participants in this study, we have identified a set of best practices for central venous line placement during times when hospital systems are stressed by disasters such as the COVID-19 pandemic.

Standard practices

Line team implementation. Each institution should determine an appropriate schedule for line team activation based on available resources and individual institutional needs. Ideally, the team should be available throughout the day, and any limitations should be communicated to the ICUs and emergency departments. The ramp-up and ramp-down of the line team should be individualized to the needs of the institution and the central venous access service line. A number of participants in this study highlighted the importance of understanding variations in individual institutional resource allocation, with this being a key to providing service at the optimal time and place.

Line cart. An adequately stocked line cart increases the efficiency of line placement procedures. This cart should have all the supplies and PPE necessary to safely perform central venous line placements and remain outside the room to reduce cross-contamination. Having an appropriately stocked cart, as pointed out by a number of participants, reduces donning and doffing of PPE, minimizes potential provider exposure, and allows a more streamlined and efficient placement of venous access. Appendix C (online only) demonstrates equipment we recommend on a line cart, including PPE.

PPE. It is paramount that proceduralists be provided with appropriate PPE. We found that the majority of our respondents were following best practices for PPE utilization—wearing an N95 mask covered by a surgical mask, protective eye wear, bouffant/surgical cap, and a gown and gloves for COVID-19+ patients. A number of sites recommended that there should be no more than two providers in the room, with a “runner” outside the room who can retrieve additional supplies as needed to preserve PPE and to minimize exposure.

Location of central lines. The preferred location of central venous access lines was relatively consistent across respondents. Given the high incidence of acute renal failure and need for acute hemodialysis in the COVID-19+ population, most centers preferably placed central lines in the left internal jugular vein, reserving the right

internal jugular vein for nontunneled hemodialysis lines. Given the high rate of COVID-19+ ICU patients requiring prone positioning, femoral lines were avoided; several centers reported placing popliteal vein lines in these patients. Subclavian lines were also discouraged, given the known increased incidence of pneumothorax over internal jugular lines. Several centers used 55-cm hemodialysis lines intended for tunneled placement in a nontunneled fashion when femoral dialysis access was needed. The cuff remained outside the patient, with the intent that the extra catheter length and stiffer catheter material would help reduce kinking and displacement when the patient required prone positioning.

Ultrasound guidance. All centers used ultrasound guidance when performing central venous access. Notably, participating sites believed that more than half of the iatrogenic complications they managed could have been prevented with meticulous use of ultrasound guidance. Ultrasound guidance has become the standard of care in placement of central lines and should continue to be used in disaster situations such as the COVID-19 pandemic, despite the additional time required to thoroughly clean the machine between uses.²¹ Participants recommended confirming wire position in the long-axis ultrasound view and using a sterile cover over the entire ultrasound probe and machine during the procedure to reduce the risk of cross-contamination. Wireless ultrasound transducers may be particularly useful in this clinical scenario.¹⁰

Postplacement confirmation. In critically ill patients, reducing complications is paramount, and early identification of complications is a key to survival of the patient. Thus, obtaining a postprocedure chest radiograph to confirm the tip location and that no pneumothorax has occurred continues to be an important step used by the majority of hospitals, even in a limited resource situation. Careful examination of the images by the treating physician to rule out pneumothorax is of particular importance in intubated patients, especially with higher pressure ventilator settings.

Needle stick prevention. We were reassured to see that there was a low incidence of needle stick injuries. In stressful situations, it is important to continue to practice safely, particularly with sharps and sharps disposal. Stressful and unfamiliar working conditions, lack of adequate protective medical and technical equipment, and poor work routines are known to contribute to needle stick injuries.²² Using an experienced, well-prepared team allows the repetition and expertise needed to reduce needle stick injuries. During this particular pandemic, patients who are COVID-19+ or COVID-19PUI must be handled with the same care, caution, and PPE.

Management of hypercoagulability and line thrombosis. Hypercoagulability in the COVID-19+ population is well established.²³⁻²⁵ We found variability among hospitals in reporting their experience with thrombosed

central lines; consequently, prevention strategies also differed. The majority of thrombosed lines were nontunneled HDCs, and the thrombosis presumably occurred during continuous venovenous hemofiltration, a known complication of a low-flow hemodialysis session.²⁶ However, we were surprised to find the large number of TLCs that also thrombosed. Some participants recommended running continuous infusions of low-dose heparinized saline through any lines that are not being used for other infusions.

Complications. Complications secondary to central venous line placement are always expected; however, the overall complication rate of 0.4% when central venous lines are placed by dedicated line teams is significantly lower than the rate of up to 15% that has been previously published.^{27,28} The incidence of arterial cannulation during central venous access has been reported to be in the range of 4.2% to 9.3% of all line placements.²⁹ In a study of 539 central venous catheter placements under ultrasound and fluoroscopy guidance, 486 of the lines were primarily placed by a surgical trainee.³⁰ The associated complication rate was 8.4%, 93% of which were arterial punctures. This suggests that a dedicated line team may not only increase efficiency of provider utilization in a pandemic but also reduce complications in a fragile at-risk population.

Limitations

As with all studies using retrospective, self-reported data, there is a possibility of reporting error or inaccuracy. To minimize this risk, we standardized the data points with specific definitions and carefully reviewed the submitted data to identify any discrepancies. All discrepancies were clarified individually with the participating investigator. Our study would be strengthened by a matched contemporaneous comparison group of hospitals that did not implement a central venous access line team or designate a group to place lines. Another valuable comparison would be the rate of complications at participating hospitals before the pandemic. However, these types of studies require a complex study design with recruitment of matched hospitals and abstraction of data that were not readily available during the pandemic. This was not feasible at the time of the study but could be performed in the future to quantify the impact of line teams on the incidence of iatrogenic central venous access complications. Lacking this, we relied on historical data in the literature for iatrogenic complication rates of central venous line procedures and anatomic preferences for central venous line placement.

These data were collected at the height of the pandemic for many participating institutions. As such, we sought to describe practice patterns that could possibly be useful to other institutions in preparing for future waves of the pandemic or other health care crises, using data that were easily accessible to participating

institutions during the potentially chaotic time. This study serves as a hypothesis-generating study that brings up several granular issues relevant to the effectiveness of line teams, requiring more laborious data extraction that should be investigated in the future. A study examining the cost effectiveness of maintaining a line cart and dedicating personnel to line teams, balanced against the potential decrease in procedural complications and increased efficiency, would provide insight into the financial burden of implementing this intervention. Comparison of the degree of change in volume of central line placements before the pandemic to during the pandemic, when the line teams were in place, would quantify the magnitude of the line placement challenge.

The unit of analysis in this study was the hospital. Patient-specific data were collected only in the case of complications and line placement in prone patients. Future studies using patient-specific data addressing issues such as whether the rates of line sepsis were influenced by the pandemic would provide further insight into the impact of the pandemic on management of central venous access.

As physicians learn more about managing patients with COVID-19, practice patterns may change with regard to line team structure and function, preferred anatomic locations, and other technical issues. A follow-up study in the future regarding "lessons learned" from central venous access during the pandemic and the associated changes in practice patterns in response would be valuable.

CONCLUSIONS

The implementation of a dedicated central venous access line team is a way in which physicians trained in percutaneous central venous access can make a contribution to a stressed health care system during a pandemic or other health care crisis. A line team composed of physicians with vascular skill sets provides relief to resource-constrained ICU, ward, and emergency medicine teams with a low rate of iatrogenic complications relative to historical reports. We recommend that a plan for central venous access line team implementation be in place for future health care emergencies, including staffing, a dedicated line cart, recommendations on the optimal anatomic site and technique, and a method to track complications.

We are deeply grateful to Gabriela Flores for her unfailing dedication as project coordinator. We thank Morad Sallam, MD, for assistance in testing and refining the data collection instrument.

AUTHOR CONTRIBUTIONS

Conception and design: TC, DJ, DR, PL, RoC, ShS, MW, KW
Analysis and interpretation: TC, DJ, DR, KW

Data collection: TC, DJ, DR, PL, RoC, ShS, MW, CA, PA, SA, BA, MB, DB, CFB, WB, CAB, FB, LB, KCO, AmC, MC, SC,

AMC, EC, AnC, RaC, GDC, SE, YE, PF, AF, AG, CG, LG, NG, GG, DH, CWH, CAH, YH, NI, LJ, JJ, AJ, LK, MRK, MK, IK, BK, AK, CJL, AL, ML, CTL, BL, GLP, JM, RGM, NMor, RLM, NMou, DN, JN, LO, JP, ZR, AR, HR, AGR, LR, CS, GS, MarS, AjS, AnS, MJS, MaIS, SaS, JS, BS, MatS, IS, RS, VS, ScS, TT, BT, ST, AV, GW, MSW, SW, JKY, JY, WZ, SZ, KW

Writing the article: TC, DJ, DR, PL, KW

Critical revision of the article: TC, DJ, DR, PL, RoC, ShS, MW, CA, PA, SA, BA, MB, DB, CFB, WB, CAB, FB, LB, KCO, AmC, MC, SC, AMC, EC, AnC, RaC, GDC, SE, YE, PF, AF, AG, CG, LG, NG, GG, DH, CWH, CAH, YH, NI, LJ, JJ, AJ, LK, MRK, MK, IK, BK, AK, CJL, AL, ML, CTL, BL, GLP, JM, RGM, NMor, RLM, NMou, DN, JN, LO, JP, ZR, AR, HR, AGR, LR, CS, GS, MarS, AjS, AnS, MJS, MaIS, SaS, JS, BS, MatS, IS, RS, VS, ScS, TT, BT, ST, AV, GW, MSW, SW, JKY, JY, WZ, SZ, KW

Final approval of the article: TC, DJ, DR, PL, RoC, ShS, MW, CA, PA, SA, BA, MB, DB, CFB, WB, CAB, FB, LB, KCO, AmC, MC, SC, AMC, EC, AnC, RaC, GDC, SE, YE, PF, AF, AG, CG, LG, NG, GG, DH, CWH, CAH, YH, NI, LJ, JJ, AJ, LK, MRK, MK, IK, BK, AK, CJL, AL, ML, CTL, BL, GLP, JM, RGM, NMor, RLM, NMou, DN, JN, LO, JP, ZR, AR, HR, AGR, LR, CS, GS, MarS, AjS, AnS, MJS, MaIS, SaS, JS, BS, MatS, IS, RS, VS, ScS, TT, BT, ST, AV, GW, MSW, SW, JKY, JY, WZ, SZ, KW

Statistical analysis: Not applicable

Obtained funding: Not applicable

Overall responsibility: KW

TC, DJ, and DR participated equally and share co-first authorship.

REFERENCES

1. COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University. Available at: <https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>. Accessed June 10, 2020.
2. Pericàs JM, Hernandez-Meneses M, Sheahan TP, Quintana E, Ambrosioni J, Sandoval E, et al. COVID-19: from epidemiology to treatment. *Eur Heart J* 2020;41:2092-112.
3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 2020 Feb 24. [Online ahead of print].
4. Ng JJ, Luo Y, Phua K, Choong AM. Acute kidney injury in hospitalized patients with coronavirus disease 2019 (COVID-19): a meta-analysis. *J Infect* 2020 May 8. [Online ahead of print].
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. [published correction appears in *Lancet* 2020;395:1038]. *Lancet* 2020;395:1054-62.
6. Vannucci A, Jeffcoat A, Ifune C, Salinas C, Duncan JR, Wall M. Special article: retained guidewires after intraoperative placement of central venous catheters. *Anesth Analg* 2013;117:102-8.
7. Sheth PD, Simons JP, Robichaud DI, Ciaranello AL, Schanzer A. Development of a surgical workforce access

- team in the battle against COVID-19. *J Vasc Surg* 2020;72:414-7.
8. Ilonzo N, Vouyouka A, Han D, Tadros R, Kim SY, Love B, et al. The importance of a centralized line service during the COVID-19 pandemic. *J Vasc Surg* 2020;72:403-4.
 9. American Society of Anesthesiologists Task Force on Central Venous Access, Rupp SM, Apfelbaum JL, Blitt C, Caplan RA, Connis RT, Domino KB, et al. Practice guidelines for central venous access: a report by the American Society of Anesthesiologists Task Force on Central Venous Access. *Anesthesiology* 2012;116:539-73.
 10. Scoppettuolo G, Biasucci DG, Pittiruti M. Vascular access in COVID-19 patients: smart decisions for maximal safety. *J Vasc Access* 2020;21:408-10.
 11. Conwell P, Aniskiewicz M, Ghidini J, DeVaux L, Perazella M, Ciullian J. A hospital-based program to reduce central line-associated bloodstream infections among hospitalized patients receiving hemodialysis using a central venous catheter for vascular access. *Nephrol Nurs J* 2019;46:587-90.
 12. Legemaat MM, Jongerden IP, van Rens RM, Zielman M, van den Hoogen A. Effect of a vascular access team on central line-associated bloodstream infections in infants admitted to a neonatal intensive care unit: a systematic review. *Int J Nurs Stud* 2015;52:1003-110.
 13. Pathak R, Gangina S, Jairam F, Hinton K. A vascular access and midlines program can decrease hospital-acquired central line-associated bloodstream infections and cost to a community-based hospital. *Ther Clin Risk Manag* 2018;14:1453-6.
 14. Lawrence PF, Baril DT, Woo K. Investigating uncommon vascular diseases using the Vascular Low Frequency Disease Consortium. *J Vasc Surg* 2020 Jan 18. [Online ahead of print].
 15. Mouawad NJ, Cuff RF, Hultgren R, Chuen J, Galeazzi E, Wohlauer M. The Vascular Surgery COVID-19 Collaborative (VASCC). *J Vasc Surg* 2020;72:379-80.
 16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42:377-81.
 17. Aitken P, Leggat P. Considerations in mass casualty and disaster management. In: Blaivas M, editor. *Emergency medicine: an international perspective*. Rijeka: IntechOpen; 2012. p. 145-82.
 18. Sasangohar F, Jones SL, Masud FN, Vahidy FS, Kash BA. Provider burnout and fatigue during the COVID-19 pandemic: lessons learned from a high-volume intensive care unit. *Anesth Analg* 2020;131:106-11.
 19. Rasmussen TE, Koelling EE. A military perspective on the vascular surgeon's response to the COVID-19 pandemic. *J Vasc Surg* 2020;71:1821-2.
 20. Christie B, Weber P, DeMillo A, Chandler K, Reeves J, Anderson B, et al. Alarming rise in virus cases as states roll back lockdowns. Available at: <https://apnews.com/feb4c26d9364497cf82ee7c0c1b1b3d5>. Accessed June 11, 2020.
 21. Lamperti M, Bodenham AR, Pittiruti M, Blaivas M, Augoustides JG, Elbarbary M, et al. International evidence-based recommendations on ultrasound-guided vascular access. *Intensive Care Med* 2012;38:1105-17.
 22. Wicker S, Stirn AV, Rabenau HF, von Gierke L, Wutzler S, Stephan C. Needlestick injuries: causes, preventability and psychological impact. *Infection* 2014;42:549-52.
 23. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. *Thromb Haemost* 2020;120:998-1000.
 24. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. *Ann Intern Med* 2020 May 6. [Online ahead of print].
 25. Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res* 2020;191:145-7.
 26. Oudemans-van Straaten HM, Wester JPJ, de Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? *Intensive Care Med* 2006;32:188-202.
 27. McGee DC, Gould MK. Preventing complications of central venous catheterization. *N Engl J Med* 2003;348:1123-33.
 28. Merrer J, De Jonghe B, Colliot F, Lefrant JU, Raffy B, Barre E, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. *JAMA* 2001;286:700-7.
 29. Kornbau C, Lee KC, Hughes GD, Firstenberg MS. Central line complications. *Int J Crit Illn Inj Sci* 2015;5:170-8.
 30. Hameeteman M, Bode AS, Peppelenbosch AG, van der Sande FM, Tordoir JH. Ultrasound-guided central venous catheter placement by surgical trainees: a safe procedure? *J Vasc Access* 2010;11:288-92.

Submitted May 21, 2020; accepted Jun 22, 2020.

Additional material for this article may be found online at www.jvascsurg.org.

Appendix A (online only). Hospitals represented in this study

Country	State	Hospital
Canada		Vancouver General Hospital
France		Ambroise Paré University Hospital, AP-HP
Germany		University Medical Center Hamburg-Eppendorf
Greece		General Hospital of Athens KAT
India		Medanta Hospital
		Postgraduate Institute of Medical Education and Research
Italy		Policlinico Gaetano Martino
Korea (South)		Kyung Hee University Hospital at Gangdong
Mexico		Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
New Zealand		Waikato Hospital
Singapore		National University Hospital
Sri Lanka		National Institute of Nephrology Dialysis and Transplantation
Switzerland		University Hospital Zurich
	Arizona	Banner University Medical Center-Tucson
	Arizona	Mayo Clinic Hospital
	California	Community Regional Medical Center
	California	Olive View-UCLA Medical Center
	California	Palo Alto Veterans Affairs Medical Center
	California	Ronald Reagan UCLA Medical Center
	California	Veterans Affairs Greater Los Angeles
	Colorado	Rocky Mountain Regional Veterans Affairs Medical Center
	Colorado	Rose Medical Center
	Colorado	University of Colorado Anschutz Medical Campus
	Iowa	University of Iowa Hospitals and Clinics
	Illinois	Loyola University Medical Center
	Illinois	NorthShore University Health System
	Illinois	Northwestern Memorial Hospital
	Indiana	Eskenazi Health
	Indiana	Indiana University Health Methodist Hospital
	Indiana	Indiana University Health North Hospital
	Indiana	Indiana University Health West Hospital
	Louisiana	Our Lady of the Lake
	Louisiana	West Jefferson Medical Center
	Massachusetts	Boston Medical Center
	Massachusetts	Massachusetts General Hospital
	Massachusetts	University of Massachusetts Medical Center
	Maryland	The Johns Hopkins Hospital
	Michigan	Henry Ford Hospital
	Michigan	McLaren Bay Region
	Michigan	McLaren Flint
	Missouri	St. Louis University Hospital
	New Jersey	Overlook Medical Center
	New Jersey	Rutgers Robert Wood Johnson University Hospital
	New Jersey	University Hospital
	New York	Jacobi Medical Center
	New York	Montefiore Medical Center
	New York	Mount Sinai Brooklyn
	New York	The Mount Sinai Hospital

Appendix A (online only). Continued.

Country	State	Hospital
	New York	Mount Sinai Queens
	New York	NewYork-Presbyterian Columbia University Medical Center
	New York	NewYork-Presbyterian Queens
	New York	North Shore University Hospital, Northwell Health
	New York	Weill Cornell Medicine
	Texas	Audie L. Murphy Veterans Affairs Hospital
	Texas	Dallas Veterans Affairs Medical Center
	Texas	Memorial Hermann-Texas Medical Center
	Texas	University of Texas Health Science Center at San Antonio University Hospital
	Utah	University of Utah Hospital
	Virginia	Virginia Commonwealth University Medical Center
	Washington	University of Washington Medical Center

Appendix B (online only). Items placed on dedicated line carts used by line teams

Item	%
Central line kits	100
Sterile gloves	97.1
Sterile gowns	97.1
Sterile preparation sticks	94.3
Sterile gauze	94.3
Ultrasound probe cover	94.3
Selection of syringes	91.4
Sterile saline flush	91.4
Sutures	91.4
Masks	91.4
Bouffant hats	85.7
Selection of hypodermic needles	80.0
Surgical towels	80.0
Tape	77.1
Selection of sterile drapes	77.1
Face shields	77.1
Lidocaine	74.3
Micropuncture sets	74.3
3-way stopcock	71.4
Antimicrobial dressing	71.4

Appendix C (online only). Recommended items on a dedicated line cart

PPE
Gloves
Gowns
Bouffant head covering
Masks: surgical, N95
Face shields
Boot covers
Nonsterile items
Tape
Coban
Arm boards
Sterile items
Central line kits
Nontunneled hemodialysis access kits
Arterial line kits (Arrow, micropuncture)
12-inch extension tubing
Surgical towels
Drapes: for arterial lines, central lines
Sterile gloves
Sterile gowns
Sterile preparation sticks
Sterile gauze
Selection of syringes
Selection of hypodermic needles
Suture
Ultrasound probe cover
Lidocaine
3-way stopcock
Antimicrobial dressing

PPE, Personal protective equipment.